ArticleIranian journal of pharmaceutical research : IJPR
Evaluating the Cardioprotective Effects of Melatonin in Non-metastatic Breast Cancer Patients Receiving Doxorubicin Plus Cyclophosphamide: A Triple-Blind, Placebo-Controlled Randomized Controlled Trial.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nutritional Prevention of Oxidative Stress-Induced Cardiotoxicity in Pediatric Cardio-Oncology: Molecular Mechanisms and Translational Perspectives-A Narrative Review.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Doxorubicin, one of the most widely used chemotherapy drugs, has several side effects, including cardiotoxicity. Objectives: We investigated the effect of melatonin on doxorubicin-induced cardiotoxicity in breast cancer patients treated with a regimen of doxorubicin plus cyclophosphamide (AC). Methods: This is a triple-blind, placebo-controlled, randomized clinical trial conducted at the Cancer Institute of Imam Khomeini Hospital, Tehran University of Medical Sciences. Using the block randomization method, 63 breast cancer patients participated in the study and were randomly divided into two groups of 32 and 31, receiving melatonin (10 mg) and a placebo, respectively. The chemotherapy regimen for these patients included doxorubicin 60 mg/m Results: The echocardiography showed that after the intervention, the left ventricular ejection fraction (LVEF) was higher in the melatonin group than in the placebo group, but it was insignificant. Meanwhile, the average global longitudinal strain (GLS) was significantly higher in the melatonin group than in the placebo group at the end of the study. The cTnI and CK-MB biomarker levels were lower in the melatonin group compared to the placebo group. These changes were significant for cTnI but not for CK-MB. Conclusions: Melatonin may be effective in the prevention of doxorubicin-induced cardiotoxicity based on the improvement in GLS and biomarker levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.